BNP Paribas Financial Markets
TPTX

BNP Paribas Financial Markets’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,367
Closed -$855K – 5117
2022
Q2 		$855K Sell
11,367
-11,662
-51% -$518K ﹤0.01% 2308
2022
Q1 		$618K Sell
23,029
-8,149
-26% -$274K ﹤0.01% 2636
2021
Q4 		$1.49M Buy
31,178
+19,917
+177% +$890K ﹤0.01% 2288
2021
Q3 		$748K Buy
11,261
+6,894
+158% +$491K ﹤0.01% 2538
2021
Q2 		$341K Sell
4,367
-628
-13% -$46.4K ﹤0.01% 2705
2021
Q1 		$472K Sell
4,995
-21,833
-81% -$2.6M ﹤0.01% 2591
2020
Q4 		$3.27M Buy
26,828
+18,756
+232% +$2.05M 0.01% 1363
2020
Q3 		$705K Buy
8,072
+4,806
+147% +$335K ﹤0.01% 2000
2020
Q2 		$211K Sell
3,266
-10,740
-77% -$620K ﹤0.01% 2460
2020
Q1 		$626K Buy
14,006
+10,235
+271% +$544K ﹤0.01% 2230
2019
Q4 		$235K Buy
3,771
+2,822
+297% +$134K ﹤0.01% 2881
2019
Q3 		$35.7K Buy
949
+807
+568% +$35.1K ﹤0.01% 3663
2019
Q2 		$5.78K Buy
+142
New +$5.07K ﹤0.01% 4220

BNP Paribas Financial Markets's TPTX Position: Q3 2022 in Review

BNP Paribas Financial Markets sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 11,367 shares — an estimated $855K sold.

BNP Paribas Financial Markets first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $3.27M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • BNP Paribas Financial Markets reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 11,367 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $855K.
  • BNP Paribas Financial Markets first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • BNP Paribas Financial Markets's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.27M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2022, filed 15 Nov 2022.